Abstract
Gallium is antiproliferative to many types of cancer, due primarily to its ability to act as a non-functional mimic of ferric iron (Fe3+). Because Fe3+ is needed for ribonucleotide reductase activity — and thus DNA synthesis — gallium can inhibit DNA production and cell division. Diagnostic gallium scans have shown that hepatocellular carcinoma (HCC) is commonly avid for gallium. Furthermore, in vitro studies have found that gallium nitrate, and particularly gallium maltolate (GaM), have dose-dependent antiproliferative activity against HCC cell lines. Rationale thus exists to use GaM, an orally active compound that has been well tolerated in Phase I clinical trials, to treat patients whose HCC is gallium-avid in a gallium scan. Because gallium absorbed from orally administered GaM is bound predominately to serum transferrin, which travels to all tissues in the body, GaM has the potential to treat even distant metastases. A patient with advanced HCC (20 x 10 cm primary tumor, ascites around liver and spleen, resistant to sorafenib (Nexavar®)), whose cancer was highly gallium-avid in a 67Ga-scan, was treated with oral gallium maltolate at 1500 mg/day q.d. After four weeks of treatment, the patient had a large reduction in pain, with greatly increased mobility and quality of life, and significantly lowered serum bilirubin and inflammation- related liver enzymes. At eight weeks, CT scans showed apparent necrosis of the tumor.
Keywords: Gallium, gallium maltolate, gallium scan, hepatocellular carcinoma, HCC, antiproliferative activity, GaM treatment, Contemporaneous CT images, metastatic prostate carcinoma, cancer-associated hypercalcemia, lymphomas, GALLIUM SCANNING, ANTICANCER MECHANISMS
Anti-Cancer Agents in Medicinal Chemistry
Title: Hepatocellular Carcinoma Detection by Gallium Scan and Subsequent Treatment by Gallium Maltolate: Rationale and Case Study
Volume: 11 Issue: 6
Author(s): Lawrence R. Bernstein, Jacobus J.M. van der Hoeven and Robbert O. Boer
Affiliation:
Keywords: Gallium, gallium maltolate, gallium scan, hepatocellular carcinoma, HCC, antiproliferative activity, GaM treatment, Contemporaneous CT images, metastatic prostate carcinoma, cancer-associated hypercalcemia, lymphomas, GALLIUM SCANNING, ANTICANCER MECHANISMS
Abstract: Gallium is antiproliferative to many types of cancer, due primarily to its ability to act as a non-functional mimic of ferric iron (Fe3+). Because Fe3+ is needed for ribonucleotide reductase activity — and thus DNA synthesis — gallium can inhibit DNA production and cell division. Diagnostic gallium scans have shown that hepatocellular carcinoma (HCC) is commonly avid for gallium. Furthermore, in vitro studies have found that gallium nitrate, and particularly gallium maltolate (GaM), have dose-dependent antiproliferative activity against HCC cell lines. Rationale thus exists to use GaM, an orally active compound that has been well tolerated in Phase I clinical trials, to treat patients whose HCC is gallium-avid in a gallium scan. Because gallium absorbed from orally administered GaM is bound predominately to serum transferrin, which travels to all tissues in the body, GaM has the potential to treat even distant metastases. A patient with advanced HCC (20 x 10 cm primary tumor, ascites around liver and spleen, resistant to sorafenib (Nexavar®)), whose cancer was highly gallium-avid in a 67Ga-scan, was treated with oral gallium maltolate at 1500 mg/day q.d. After four weeks of treatment, the patient had a large reduction in pain, with greatly increased mobility and quality of life, and significantly lowered serum bilirubin and inflammation- related liver enzymes. At eight weeks, CT scans showed apparent necrosis of the tumor.
Export Options
About this article
Cite this article as:
R. Bernstein Lawrence, J.M. van der Hoeven Jacobus and O. Boer Robbert, Hepatocellular Carcinoma Detection by Gallium Scan and Subsequent Treatment by Gallium Maltolate: Rationale and Case Study, Anti-Cancer Agents in Medicinal Chemistry 2011; 11 (6) . https://dx.doi.org/10.2174/187152011796011046
DOI https://dx.doi.org/10.2174/187152011796011046 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
Call for Papers in Thematic Issues
Induction of cell death in cancer cells by modulating telomerase activity using small molecule drugs
Telomeres are distinctive but short stretches present at the corners of chromosomes and aid in stabilizing chromosomal makeup. Resynthesis of telomeres supported by the activity of reverse transcriptase ribonucleoprotein complex telomerase. There is no any telomerase activity in human somatic cells, but the stem cells and germ cells undergone telomerase ...read more
Role of natural compounds as anti anti-cancer agents
Cancer is considered the leading cause of worldwide mortality, accounting for nearly 10 million deaths in 2022. Cancer outcome can be improved through an appropriate screening and early detection and through an efficient clinical treatment. Chemotherapy remains an important approach in treatment o f several types of cancers, even though ...read more
Signaling and enzymatic modulators in cancer treatment
Cancer accounts for nearly 10 million deaths in 2022 and is considered the leading cause of worldwide mortality. Cancer outcome can be improved through an appropriate screening and early detection and through an efficient clinical treatment. Chemotherapy, radiotherapy and surgery are the most important approach for the treatment of several ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Transposable Elements in Cancer and Other Human Diseases
Current Cancer Drug Targets Aromatase Inhibitors: A New Paradigm in Breast Cancer Treatment
Current Medicinal Chemistry - Anti-Cancer Agents Targeting Never-In-Mitosis-A Related Kinase 5 in Cancer: A Review
Current Medicinal Chemistry Fetal Mesenchymal Stem Cells in Cancer Therapy
Current Stem Cell Research & Therapy Characterization and Management of Cutaneous Side Effects Related to the Immunosuppressive Treatment in Solid Organ Recipients
Current Drug Targets Structure of Multidrug-Resistance Proteins of the ATP-Binding Cassette (ABC) Superfamily
Current Medicinal Chemistry - Anti-Cancer Agents Preclinical Development of Novel Anti-Glioma Drugs Targeting the Endoplasmic Reticulum Stress Response
Current Pharmaceutical Design Targeting ABCB1 and ABCC1 with their Specific Inhibitor CBT-1<sup>®</sup> can Overcome Drug Resistance in Osteosarcoma
Current Cancer Drug Targets Nanotechnology and Radiopharmaceuticals: Diagnostic and Therapeutic Approaches
Current Drug Delivery Imatinib Reduces the Vasculogenic Potential of Plastic Tumor Cells
Current Angiogenesis (Discontinued) Non-Infectious Complications of Immunosuppressant Medications in Renal Transplant Patients
Current Clinical Pharmacology The Ambidextrous Cyclooxygenase: An Enduring Target
Inflammation & Allergy - Drug Targets (Discontinued) The Therapeutic Potential of 4-1BB (CD137) in Cancer
Current Cancer Drug Targets Molecular Imaging of Apoptosis with Radio-Labeled Annexin A5 Focused on the Evaluation of Tumor Response to Chemotherapy
Anti-Cancer Agents in Medicinal Chemistry Telomerase as Drug and Drug Target for the Treatment of Thyroid Cancer
Current Drug Targets - Immune, Endocrine & Metabolic Disorders Color-Coded Fluorescent Protein Imaging of Angiogenesis: The AngioMouse® Models
Current Pharmaceutical Design Cytotoxic and Apoptogenic Activity of a Methanolic Extract from the Marine Invertebrate Ciona intestinalis on Malignant Cell Lines
Medicinal Chemistry Recent Patents on Nucleic Acid-Based Antiviral Therapeutics
Recent Patents on Anti-Infective Drug Discovery The MYC Oncogene as a Cancer Drug Target
Current Cancer Drug Targets Computational Studies of HIV-1 Integrase and its Inhibitors
Current Computer-Aided Drug Design